{"id":"madalena-association","safety":{"commonSideEffects":[]},"_chembl":null,"_dailymed":null,"mechanism":{"_ai_source":"claude-haiku-4.5","explanation":"Without access to the specific composition of MADALENA ASSOCIATION, the exact mechanism cannot be determined. As a combination product in Phase 3 development by EMS (a Brazilian pharmaceutical company), it is designed to provide synergistic therapeutic effects through its component agents. The specific mechanism would depend on the individual drugs included in the association.","oneSentence":"MADALENA is a fixed-dose combination product developed by EMS, likely containing multiple active pharmaceutical ingredients to address a specific therapeutic indication.","_ai_confidence":"low"},"_scrapedAt":"2026-03-28T01:20:01.141Z","_scrapedBy":"cloudflare-swarm","_wikipedia":null,"indications":{"approved":[]},"trialDetails":[{"nctId":"NCT04670666","phase":"PHASE3","title":"Efficacy and Safety of Madalena Association in the Treatment of Type II Diabetes Mellitus","status":"RECRUITING","sponsor":"EMS","startDate":"2024-11-18","conditions":"Type 2 Diabetes Mellitus","enrollment":270}],"_emaApprovals":[],"_faersSignals":[],"_approvalHistory":[],"publicationCount":23,"rwe":[],"genericFilers":[],"relatedDrugs":[],"labelChanges":[],"biosimilarFilings":[],"pricing":[],"formularyStatus":[],"manufacturing":[],"companionDiagnostics":[],"competitors":[],"timeline":[],"patents":[],"ownershipHistory":[],"trials":[],"biosimilars":[],"latestUpdates":[],"references":[],"tags":[],"ecosystem":[],"genericManufacturerList":[],"offLabel":[],"developmentCodes":[],"aliases":[],"phase":"phase_3","status":"active","brandName":"MADALENA ASSOCIATION","genericName":"MADALENA ASSOCIATION","companyName":"EMS","companyId":"ems","modality":"Small molecule","firstApprovalDate":"","aiSummary":"","enrichmentLevel":3,"visitCount":0,"trialStats":{"total":0,"withResults":0},"verificationStatus":"partial","dataCompleteness":{"mechanism":true,"indications":false,"safety":false,"trials":true,"score":2}}